TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 353623

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (750 mg per day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (1,000 mg per day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 31875616

Group type: EXPERIMENTAL
Intervention: Sacrubitril/Valsartan
Number of subjects: 120

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 120
Study: 31145699

Group type: EXPERIMENTAL
Intervention: High-protein feeding rich in glutamate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Supplementation with glutamate, glutamine, and leucine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glutamate, glutamine, and leucine
Number of subjects: 9
Study: 28040660

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (SFX) with cisplatin (100 mg/m2 IV × 3)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Altered fractionation radiotherapy (AFX) with panitumumab (PMab; 9 mg/kg IV × 3)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (SFX)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Altered fractionation radiotherapy (AFX) with panitumumab (PMab)
Number of subjects: 320
Study: 26237830

Group type: COMPARATOR
Intervention: Anti-rheumatic drugs (ARDs) including oral celecoxib, methotrexate, and esomeprazole
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ginger-partitioned acupoint stimulation at zusanli (ST 36)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination treatment with oral sanhuangwuji powder, ginger-partitioned acupoint stimulation at zusanli (ST 36), and ARDs
Number of subjects: 180
Study: 23774436

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg daily doses
Number of subjects: 169
Study: 21672197

Group type: EXPERIMENTAL
Intervention: Specific training to record adverse effects with subsequent feedback after instruction on the process.
Number of subjects: 54

Group type: COMPARATOR
Intervention: No action taken (Control group).
Number of subjects: 54
Study: 19665415

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 16942472

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment plus progressive muscular relaxation (PMR) exercises
Number of subjects: 29

Group type: COMPARATOR
Intervention: Progressive muscular relaxation (PMR) exercises only
Number of subjects: 29
Study: 14964492

Group type: EXPERIMENTAL
Intervention: Flap surgery and laser treatment using an energy level of 0.8 W
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flap surgery and laser treatment using an energy level of 0.5 W
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flap surgery only (control)
Number of subjects: 12
Study: 12237921

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11) 100 mg/m² over 90 minutes, Paclitaxel 175 mg/m² over 3 hours, Carboplatin AUC 5 over 30 minutes, administered on the first day of each 21-day cycle.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11), Paclitaxel, and Carboplatin combination therapy.
Number of subjects: 40
Study: 9797181

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 7639224

Group type: EXPERIMENTAL
Intervention: 3 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 6 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 10 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Number of subjects: 91
Study: 2562137

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/day in addition to previous therapy with digitalis and diuretics
Number of subjects: 38

Group type: COMPARATOR
Intervention: Continuation of previous therapy (Control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of changes between groups
Number of subjects: 38
Study: 362528

Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nonimmune control human serum
Number of subjects: 136
Study: 29985265

Group type: EXPERIMENTAL
Intervention: ARV drugs detected in HIV-infected young women
Number of subjects: 2526

Group type: COMPARATOR
Intervention: ARV drugs detected in HIV-uninfected young women
Number of subjects: 2526

Group type: EXPERIMENTAL
Intervention: ARV drugs detected in seroconverters
Number of subjects: 2526

Group type: EXPERIMENTAL
Intervention: HIV drug resistance in young women with genotyping results
Number of subjects: 2526

Group type: EXPERIMENTAL
Intervention: HIV drug resistance in seroconverters with genotyping results
Number of subjects: 2526
Study: 25944685

Group type: EXPERIMENTAL
Intervention: QTinno (fully automated, 5 replicates)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HeartSignals (computer-assisted manual, 3 replicates)
Number of subjects: 24

Group type: COMPARATOR
Intervention: VERITAS (automated commercial algorithm)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HeartSignals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: QTinno
Number of subjects: 24
Study: 25139110

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mixed Maxillary Expansion (MME)
Number of subjects: 42
Study: 22618923

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 723

Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 723
Study: 19825505

Group type: EXPERIMENTAL
Intervention: Combination therapy with dutasteride (0.5 mg) and tamsulosin (0.4 mg)
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Tamsulosin monotherapy
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Dutasteride monotherapy
Number of subjects: 4844
Study: 17588698

Group type: EXPERIMENTAL
Intervention: Immediate drain site radiotherapy 21Gy in three fractions (XRT arm)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 61
Study: 15601811

Group type: EXPERIMENTAL
Intervention: Encapsulated sumatriptan (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonencapsulated sumatriptan (100 mg)
Number of subjects: 10
Study: 11883108

Group type: EXPERIMENTAL
Intervention: Invasive diagnostics and revascularization therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case fatality rate after 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalence of myocardial infarction
Number of subjects: 0
Study: 10352534

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) transdermal treatment 50 micrograms (TTS 50) continuously administered plus Medroxyprogesterone Acetate (MPA) 10 mg/die for twelve days a month (Group A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Conjugated Equine Estrogens (CEE) 0.625 mg/die continuously plus MPA for twelve days a month (Group B)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Estradiol transdermal 50 micrograms continuously plus MPA 2.5 mg/die continuously (Group C)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/die continuously plus MPA 2.5 mg/die continuously (Group D)
Number of subjects: 110
Study: 8749695

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) with total body irradiation
Number of subjects: 60
Study: 1780205

Group type: EXPERIMENTAL
Intervention: 1.4 ml/kg of 95% ethanol, plus diluent
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diluent (placebo condition)
Number of subjects: 8
Study: 6109938

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine (3 doses at one-month intervals)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diphtheria/tetanus/polio vaccine (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 100
Study: 30887865

Group type: EXPERIMENTAL
Intervention: Citalopram 4 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Citalopram 16 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Citalopram (7.5 mg intravenously)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Citalopram (all doses)
Number of subjects: 45
Study: 27933667

Group type: EXPERIMENTAL
Intervention: SleepMapper
Number of subjects: 61
Study: 25687484

Group type: EXPERIMENTAL
Intervention: Facilitatory Kinesio tape
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inhibitory Kinesio tape
Number of subjects: 33

Group type: COMPARATOR
Intervention: No tape (tapeless condition)
Number of subjects: 33
Study: 24433837

Group type: EXPERIMENTAL
Intervention: Exercise Assisted Reduction then Stop (EARS) intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 22779219

Group type: EXPERIMENTAL
Intervention: Topical gingival patch
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 26
Study: 19641261

Group type: EXPERIMENTAL
Intervention: Use of online lifestyle diary with computer assistant feedback
Number of subjects: 118

Group type: COMPARATOR
Intervention: Use of online lifestyle diary without computer assistant feedback
Number of subjects: 118
Study: 17656440

Group type: EXPERIMENTAL
Intervention: Caffeine capsules (dose = 5 mg kg(‐1)) and saline infusion ([ADR] = 0.62 nm)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo capsules and saline infusion ([ADR] = 0.29 nm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Placebo capsules and ADR infusion ([ADR] = 1.19 nm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine capsules (dose = 5 mg kg(‐1)) and ADR infusion ([ADR] = 0.93 nm)
Number of subjects: 8
Study: 16275937

Group type: EXPERIMENTAL
Intervention: PCF (paclitaxel 175 mg/m2 on day 1, cisplatin 100 mg/m2 on day 2, FU 500 mg/m2 continuous infusion on days 2 through 6)
Number of subjects: 382

Group type: COMPARATOR
Intervention: CF (cisplatin 100 mg/m2 on day 1 plus FU 1000 mg/m2 continuous infusion on days 1 through 5)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: PCF
Number of subjects: 382

Group type: COMPARATOR
Intervention: CF
Number of subjects: 382
Study: 12064491

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (experimental group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 83
Study: 10215237

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 46
Study: 8536900

Group type: EXPERIMENTAL
Intervention: Octreotide (25, 50, or 100 micrograms diluted in normal saline solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 100
Study: 1591117

Group type: EXPERIMENTAL
Intervention: Pinned restorations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amalgambond restorations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panavia‐Ex restorations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Copal varnish (control)
Number of subjects: 40
Study: 6690375

Group type: EXPERIMENTAL
Intervention: Picolax alone
Number of subjects: 160

Group type: COMPARATOR
Intervention: X‐Prep alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Picolax plus lavage
Number of subjects: 160

Group type: COMPARATOR
Intervention: X‐Prep plus lavage
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dietary restriction
Number of subjects: 160

Group type: COMPARATOR
Intervention: Mechanical lavage
Number of subjects: 160
Study: 31197967

Group type: EXPERIMENTAL
Intervention: Primary posterior capsulorhexis (PPCR)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No primary posterior capsulorhexis (No PPCR)
Number of subjects: 97
Study: 29362206

Group type: EXPERIMENTAL
Intervention: Digital mail invitation (e-Boks)
Number of subjects: 7200

Group type: COMPARATOR
Intervention: Paper mail invitation
Number of subjects: 7200
Study: 27116645

Group type: EXPERIMENTAL
Intervention: Graded Exercise (GE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent Exercise (IE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 24
Study: 26203643

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block plus physical therapy (PT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physical therapy (PT) alone
Number of subjects: 41
Study: 23208648

Group type: EXPERIMENTAL
Intervention: Group couple-based intervention (n=112)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Individual couple-based intervention (n=104)
Number of subjects: 216
Study: 21076241

Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving (TOPS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Internet resource comparison (control)
Number of subjects: 41
Study: 18198942

Group type: EXPERIMENTAL
Intervention: Wild-type strain of Staphylococcus aureus
Number of subjects: 16

Group type: COMPARATOR
Intervention: ClfB knock-out mutant strain of Staphylococcus aureus
Number of subjects: 16
Study: 16861591

Group type: EXPERIMENTAL
Intervention: Breast cancer risk education and prevention programs
Number of subjects: 481
Study: 14551523

Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abciximab therapy
Number of subjects: 0
Study: 10757081

Group type: EXPERIMENTAL
Intervention: Bestatin (ubenimex) 10, 30, 90, and 180 mg/day for 60 days after BMT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bestatin (ubenimex)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 65
Study: 9118049

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (150 U/kg 3 times per week for 3 weeks, increased to 300 U/kg and 450 U/kg for nonresponders)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no r‐HuEPO)
Number of subjects: 36
Study: 8353547

Group type: EXPERIMENTAL
Intervention: Antibiotic plus laser therapy (group II)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Antibiotic therapy (group I)
Number of subjects: 104
Study: 2887123

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate
Number of subjects: 0
Study: 31282699

Group type: EXPERIMENTAL
Intervention: Sad videos (n = 71)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Neutral videos (n = 65)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Sad noncriers (n = 61)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Sad criers (n = 71)
Number of subjects: 197
Study: 29205487

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 260

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 260
Study: 27038714

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1981

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES-S)
Number of subjects: 1981

Group type: EXPERIMENTAL
Intervention: Bare metal stent (BMS)
Number of subjects: 1981

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1981

Group type: COMPARATOR
Intervention: EES
Number of subjects: 1981

Group type: COMPARATOR
Intervention: ZES-S
Number of subjects: 1981
Study: 25318892

Group type: EXPERIMENTAL
Intervention: Low intensity electro-acupuncture (EA)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High intensity electro-acupuncture (EA)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Medicine-controlled (MC) group (5 mg mosapride citrate, 3 times/day for 4 weeks)
Number of subjects: 111
Study: 22434460

Group type: EXPERIMENTAL
Intervention: Arthroscopy of the hip for FAI
Number of subjects: 612
Study: 20868559

Group type: EXPERIMENTAL
Intervention: LCAHFR combined with FP chemotherapy
Number of subjects: 2030

Group type: COMPARATOR
Intervention: LCAHFR
Number of subjects: 2030
Study: 17369784

Group type: EXPERIMENTAL
Intervention: Long-term dynamic exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isometric resistance exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postural and proprioceptive exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Very low intensity exercises
Number of subjects: 0
Study: 16083533

Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronic acid and 1% silver sulfadiazine (HA-SSD)
Number of subjects: 111

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine (SSD)
Number of subjects: 111
Study: 12177656

Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise test
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bicycle exercise training session
Number of subjects: 27
Study: 8064328

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim (Bactrim)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 3399778

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triazolam and Placebo
Number of subjects: 18
Study: 31978237

Group type: EXPERIMENTAL
Intervention: CareNavRN™ intervention (home health nurse visits once per week for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CareNavRN™ intervention
Number of subjects: 40
Study: 30445611

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein, low-density lipoprotein (LDL), total cholesterol, and triglycerides
Number of subjects: 0
Study: 28294557

Group type: EXPERIMENTAL
Intervention: Terlipressin (Tp)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 41
Study: 25307976

Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoid treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no glucocorticoid treatment)
Number of subjects: 69
Study: 23506013

Group type: EXPERIMENTAL
Intervention: Intervention arm receives eight SMS messages/week, one Email/week, personalized coaching calls during weeks 0, 2, 5, 8, and 11
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control arm receives four SMS text messages
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 354
Study: 22783687

Group type: EXPERIMENTAL
Intervention: Nickel chromium brackets (OS)
Number of subjects: 38
Study: 19010943

Group type: EXPERIMENTAL
Intervention: Integrated care (ICARUSS model)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 186
Study: 16960178

Group type: EXPERIMENTAL
Intervention: CHO+Pro+Leu
Number of subjects: 16

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 16
Study: 14764753

Group type: EXPERIMENTAL
Intervention: T enanthate, 200 mg im every 2 weeks with placebo pills daily (T-only)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: T enanthate, 200 mg every 2 weeks with 5 mg finasteride daily (T+F)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo injections and pills
Number of subjects: 70
Study: 11321143

Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation presence in patients with CRVO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Factor V Leiden mutation presence in clinic control patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Association of factor V Leiden with CRVO
Number of subjects: 0
Study: 8989254

Group type: EXPERIMENTAL
Intervention: Transdermal E2 for 30 days (subgroup A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone‐acetate for 30 days (subgroup B)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Transdermal E2 plus medroxyprogesterone‐acetate for 30 days (subgroup C)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 10146972

Group type: EXPERIMENTAL
Intervention: roxithromycin 150mg twice daily
Number of subjects: 238

Group type: COMPARATOR
Intervention: cefaclor 250mg thrice daily
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 238

Group type: COMPARATOR
Intervention: cefaclor
Number of subjects: 238
Study: 2647644

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 17894113

Group type: EXPERIMENTAL
Intervention: Dilantin (diphenyldantoin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31696598

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily (QD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29070442

Group type: EXPERIMENTAL
Intervention: Social Recovery Therapy (SRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 26541060

Group type: EXPERIMENTAL
Intervention: 875 µg (35 000 IU) cholecalciferol (vitamin D3) per week
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 160
Study: 25966665

Group type: EXPERIMENTAL
Intervention: Edoxaban (15 mg single oral dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: M4 (major metabolite of edoxaban)
Number of subjects: 32
Study: 24005274

Group type: EXPERIMENTAL
Intervention: Epistop‐3 three‐balloon silicone catheter
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gauze packs
Number of subjects: 48
Study: 22243943

Group type: EXPERIMENTAL
Intervention: Normal protein diet (NP, 1 g protein:2 g carbohydrate)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low protein diet (LP, 1 g protein:4 g carbohydrate)
Number of subjects: 54

Group type: COMPARATOR
Intervention: High protein diet (HP, 1 g protein:1 g carbohydrate)
Number of subjects: 54
Study: 19710156

Group type: EXPERIMENTAL
Intervention: Vitamin E (182 mg d,l‐alpha‐tocopherol)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 17257531

Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Autograft (iliac crest bone graft)
Number of subjects: 31
Study: 15295748

Group type: EXPERIMENTAL
Intervention: Training with a 3‐dimensional computer game during a 4‐week period consisting of twelve 90‐minute sessions.
Number of subjects: 1